Literature DB >> 9621072

T-Cell response to woodchuck hepatitis virus (WHV) antigens during acute self-limited WHV infection and convalescence and after viral challenge.

S Menne1, J Maschke, M Lu, H Grosse-Wilde, M Roggendorf.   

Abstract

The infection of woodchucks with woodchuck hepatitis virus (WHV) provides an experimental model to study early immune responses during hepadnavirus infection that cannot be tested in patients. The T-cell response of experimentally WHV-infected woodchucks to WHsAg, rWHcAg, and WHcAg peptides was monitored by observing 5-bromo-2'-deoxyuridine and [2-3H]adenine incorporation. The first T-cell responses were directed against WHsAg 3 weeks after infection; these were followed by responses to rWHcAg including the immunodominant T-cell epitope of WHcAg (amino acids 97 to 110). Maximal proliferative responses were detected when the animals seroconvered to anti-WHs and anti-WHc (week 6). A decrease in the T-cell response to viral antigens coincided with clearance of viral DNA. Polyclonal rWHcAg-specific T-cell lines were established 6, 12, 18, and 24 weeks postinfection, and their responses to WHcAg peptides were assessed. Five to seven peptides including the immunodominant epitope were recognized throughout the observation period (6 months). At 12 months after infection, T-cell responses to antigens and peptides were not detected. Reactivation of T-cell responses to viral antigens and peptides occurred within 7 days after challenge of animals with WHV. These results demonstrate that a fast and vigorous T-cell response to WHsAg, rWHcAg, and amino acids 97 to 110 of the WHcAg occurs within 3 weeks after WHV infection. The peak of this response was associated with viral clearance and may be crucial for recovery from infection. One year after infection, no proliferation of T cells in response to antigens was observed; however, the WHV-specific T-cell response was reactivated after challenge of woodchucks with WHV and may be responsible for protection against WHV reinfection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9621072      PMCID: PMC110414     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection.

Authors:  C Ferrari; A Penna; A Bertoletti; A Valli; A D Antoni; T Giuberti; A Cavalli; M A Petit; F Fiaccadori
Journal:  J Immunol       Date:  1990-11-15       Impact factor: 5.422

2.  HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen.

Authors:  A Bertoletti; C Ferrari; F Fiaccadori; A Penna; R Margolskee; H J Schlicht; P Fowler; S Guilhot; F V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

Review 3.  T and B memory cells.

Authors:  J Sprent
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

Review 4.  A possible role for bcl-2 in regulating T-cell memory--a 'balancing act' between cell death and survival.

Authors:  A N Akbar; M Salmon; J Savill; G Janossy
Journal:  Immunol Today       Date:  1993-11

5.  Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen.

Authors:  C Ferrari; A Bertoletti; A Penna; A Cavalli; A Valli; G Missale; M Pilli; P Fowler; T Giuberti; F V Chisari
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

Review 6.  Role of T-cell tolerance in the persistence of hepatitis B virus infection.

Authors:  D R Milich; J Jones; J Hughes; T Maruyama
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1993-10

7.  HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection.

Authors:  R Nayersina; P Fowler; S Guilhot; G Missale; A Cerny; H J Schlicht; A Vitiello; R Chesnut; J L Person; A G Redeker; F V Chisari
Journal:  J Immunol       Date:  1993-05-15       Impact factor: 5.422

8.  Immunization with recombinant woodchuck hepatitis virus nucleocapsid antigen or hepatitis B virus nucleocapsid antigen protects woodchucks from woodchuck hepatitis virus infection.

Authors:  F Schödel; G Neckermann; D Peterson; K Fuchs; S Fuller; H Will; M Roggendorf
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

9.  Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B.

Authors:  M C Jung; U Spengler; W Schraut; R Hoffmann; R Zachoval; J Eisenburg; D Eichenlaub; G Riethmüller; G Paumgartner; H W Ziegler-Heitbrock
Journal:  J Hepatol       Date:  1991-11       Impact factor: 25.083

10.  Protection of woodchucks from infection with woodchuck hepatitis virus by immunization with recombinant core protein.

Authors:  S Roos; K Fuchs; M Roggendorf
Journal:  J Gen Virol       Date:  1989-08       Impact factor: 3.891

View more
  23 in total

Review 1.  The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection.

Authors:  Stephan Menne; Paul J Cote
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

Review 2.  The Woodchuck, a Nonprimate Model for Immunopathogenesis and Therapeutic Immunomodulation in Chronic Hepatitis B Virus Infection.

Authors:  Michael Roggendorf; Anna D Kosinska; Jia Liu; Mengji Lu
Journal:  Cold Spring Harb Perspect Med       Date:  2015-10-28       Impact factor: 6.915

3.  Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections.

Authors:  J T Guo; H Zhou; C Liu; C Aldrich; J Saputelli; T Whitaker; M I Barrasa; W S Mason; C Seeger
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Woodchuck gamma interferon upregulates major histocompatibility complex class I transcription but is unable to deplete woodchuck hepatitis virus replication intermediates and RNAs in persistently infected woodchuck primary hepatocytes.

Authors:  Mengji Lu; Beate Lohrengel; Gero Hilken; Thekla Kemper; Michael Roggendorf
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

5.  Deficiencies in the acute-phase cell-mediated immune response to viral antigens are associated with development of chronic woodchuck hepatitis virus infection following neonatal inoculation.

Authors:  Stephan Menne; Carol A Roneker; Michael Roggendorf; John L Gerin; Paul J Cote; Bud C Tennant
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

6.  Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection.

Authors:  Stephan Menne; Carol A Roneker; Brent E Korba; John L Gerin; Bud C Tennant; Paul J Cote
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

7.  Correlation of virus and host response markers with circulating immune complexes during acute and chronic woodchuck hepatitis virus infection.

Authors:  Dieter Glebe; Heike Lorenz; Wolfram H Gerlich; Scott D Butler; Ilia A Tochkov; Bud C Tennant; Paul Cote; Stephan Menne
Journal:  J Virol       Date:  2008-12-03       Impact factor: 5.103

8.  Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection.

Authors:  M Lu; G Hilken; J Kruppenbacher; T Kemper; R Schirmbeck; J Reimann; M Roggendorf
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

9.  Acute resolving woodchuck hepatitis virus (WHV) infection is associated with a strong cytotoxic T-lymphocyte response to a single WHV core peptide.

Authors:  Ina Frank; Claudia Budde; Melanie Fiedler; Uta Dahmen; Sergei Viazov; Mengji Lu; Ulf Dittmer; Michael Roggendorf
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

10.  Intrahepatic expression of genes affiliated with innate and adaptive immune responses immediately after invasion and during acute infection with woodchuck hepadnavirus.

Authors:  Clifford S Guy; Patricia M Mulrooney-Cousins; Norma D Churchill; Tomasz I Michalak
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.